cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Igm Biosciences Inc
6 own
6 watching
Current Price
$13.6
$0.76
(5.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
585.92M
52-Week High
52-Week High
28.2
52-Week Low
52-Week Low
9.74
Average Volume
Average Volume
0.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization585.92M
icon52-Week High28.2
icon52-Week Low9.74
iconAverage Volume0.4M
iconDividend Yield--
iconP/E Ratio--
What does the Igm Biosciences Inc do?
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Read More
How much money does Igm Biosciences Inc make?
News & Events about Igm Biosciences Inc.
PR Newswire
1month ago
Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ) Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ) PR Newswire STOCKHOLM, May 4, 2023 STOCKHOLM, May 4, 2023 /PRNewswire/ --The annual general...
PR Newswire
1month ago
Resolutions at the Annual General Meeting in Medivir on 4 May 2023 Resolutions at the Annual General Meeting in Medivir on 4 May 2023 PR Newswire STOCKHOLM, May 4, 2023 STOCKHOLM, May 4, 2023 /PRNewswire/ --Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual...
PR Newswire
1month ago
Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination PR...
PR Newswire
2 months ago
Medivir 2022 Annual Report published Medivir 2022 Annual Report published PR Newswire STOCKHOLM, April 4, 2023 STOCKHOLM, April 4, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR)today announces that the Annual Report for 2022 now is available at the company's website: www.medivir.com...
PR Newswire
2 months ago
Notice of Annual General Meeting of Medivir AB (publ) Notice of Annual General Meeting of Medivir AB (publ) PR Newswire STOCKHOLM, March 31, 2023 STOCKHOLM, March 31, 2023 /PRNewswire/ --The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm...
Frequently Asked Questions
Frequently Asked Questions
What is Igm Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Igm Biosciences Inc shares?
plus_minus_icon
How can I buy Igm Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Igm Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Igm Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Igm Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Igm Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Igm Biosciences Inc?
plus_minus_icon
What percentage is Igm Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Igm Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.6
$0.76
(5.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$11.66
$0.03 (0.26 %)
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$10.92
$0.75 (7.37 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$8.20
$0.55 (7.19 %)
Cullinan Oncology Inc
Cullinan Oncology Inc
$10.53
$0.37 (3.64 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$11.66
$0.03 (0.26 %)
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$10.92
$0.75 (7.37 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$8.20
$0.55 (7.19 %)
Cullinan Oncology Inc
Cullinan Oncology Inc
$10.53
$0.37 (3.64 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00